ANN ARBOR, Mich.--(BUSINESS WIRE)--Atterocor, Inc., a company developing a novel therapy for adrenal cancer, today announced that it has initiated a Phase 1 clinical trial of ATR-101 for the treatment of adrenocortical carcinoma (ACC). ATR-101 is a novel, oral drug candidate that has shown selective effects on cells derived from the adrenal cortex in a variety of preclinical studies. In addition, Atterocor has secured orphan drug designation for ATR-101 from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Orphan drug designation, which is intended to facilitate drug development for rare diseases, provides substantial benefits to the sponsor, including the potential for funding for certain clinical studies, study-design assistance, and several years of market exclusivity for the product upon regulatory approval.
Help employers find you! Check out all the jobs and post your resume.
